These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31193370)

  • 1. Analysis of risk factors and outcomes in psychiatric inpatients with tardive dyskinesia: A nationwide case-control study.
    Patel RS; Mansuri Z; Chopra A
    Heliyon; 2019 May; 5(5):e01745. PubMed ID: 31193370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical and Psychiatric Comorbidities in Bipolar Disorder: Insights from National Inpatient Population-based Study.
    Hossain S; Mainali P; Bhimanadham NN; Imran S; Ahmad N; Patel RS
    Cureus; 2019 Sep; 11(9):e5636. PubMed ID: 31700739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders.
    McEvoy J; Park T; Schilling T; Terasawa E; Ayyagari R; Carroll B
    Curr Med Res Opin; 2019 Jul; 35(7):1205-1214. PubMed ID: 30638073
    [No Abstract]   [Full Text] [Related]  

  • 4. Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia.
    Caroff SN; Mu F; Ayyagari R; Schilling T; Abler V; Carroll B
    BMC Psychiatry; 2018 Sep; 18(1):306. PubMed ID: 30249218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cross-Sectional Study on the Characteristics of Tardive Dyskinesia in Patients with Chronic Schizophrenia.
    Huang Y; Pan L; Teng F; Wang G; Li C; Jin L
    Shanghai Arch Psychiatry; 2017 Oct; 29(5):295-303. PubMed ID: 29276353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis.
    Patterson-Lomba O; Ayyagari R; Carroll B
    BMC Neurol; 2019 Jul; 19(1):174. PubMed ID: 31325958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence, clinical correlates and risk factors associated with Tardive Dyskinesia in Chinese patients with schizophrenia.
    Uludag K; Wang DM; Goodman C; Chen DC; Wang L; Zhang X
    Asian J Psychiatr; 2021 Dec; 66():102877. PubMed ID: 34638091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of Blood Biochemical Markers with Tardive Dyskinesia in Schizophrenic Patients.
    Wu Q; Yuan F; Zhang S; Liu W; Miao Q; Zheng X; Lu S; Hou K
    Dis Markers; 2022; 2022():1767989. PubMed ID: 35299866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic reviews of the effectiveness of day care for people with severe mental disorders: (1) acute day hospital versus admission; (2) vocational rehabilitation; (3) day hospital versus outpatient care.
    Marshall M; Crowther R; Almaraz-Serrano A; Creed F; Sledge W; Kluiter H; Roberts C; Hill E; Wiersma D; Bond GR; Huxley P; Tyrer P
    Health Technol Assess; 2001; 5(21):1-75. PubMed ID: 11532238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the relationship between vitamin D deficiency and comorbid heart disease in Americans with mood disorders: a cross-sectional nationwide study.
    Habib M; Jaka S; Pokhrel S; Sejdiu A; Patel A; Vashist S; Arisoyin A; Pathak M; Bachu AK; Rajaram Manoharan SVR; Mogallapu R; Patel RS
    Front Psychiatry; 2023; 14():1256126. PubMed ID: 37937234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curaçao extrapyramidal syndromes study V.
    van Harten PN; Hoek HW; Matroos GE; van Os J
    J Clin Psychiatry; 2006 Dec; 67(12):1920-7. PubMed ID: 17194270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical risk factors for the development of tardive dyskinesia.
    Solmi M; Pigato G; Kane JM; Correll CU
    J Neurol Sci; 2018 Jun; 389():21-27. PubMed ID: 29439776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hospitalization Outcomes and Comorbidities of Bulimia Nervosa: A Nationwide Inpatient Study.
    Patel RS; Olten B; Patel P; Shah K; Mansuri Z
    Cureus; 2018 May; 10(5):e2583. PubMed ID: 29984125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroleptic withdrawal in treatment-resistant patients with schizophrenia: tardive dyskinesia is not associated with supersensitive psychosis.
    Apud JA; Egan MF; Wyatt RJ
    Schizophr Res; 2003 Sep; 63(1-2):151-60. PubMed ID: 12892869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychosocial Implications of Tardive Dyskinesia in Patients With Mood Disorders Versus Schizophrenia.
    McEvoy JP
    J Clin Psychiatry; 2019 Dec; 80(6):. PubMed ID: 31846247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychiatric Comorbidities in Pediatric Inpatients With Human Immunodeficiency Virus Infection and Impact on Hospital Course: Inputs From a Case-Control Inpatient Study.
    Dias CC; Ayala V; Aliduux FA; Basith SA; Sejdiu A; Nakaska MM; Akter S; Mathialagan K; Majumder P
    Cureus; 2021 Jun; 13(6):e15686. PubMed ID: 34277275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.
    McIntyre RS; Calabrese JR; Nierenberg AA; Farahmand K; Yonan C; Siegert S; Burke J
    J Affect Disord; 2019 Mar; 246():217-223. PubMed ID: 30583148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.